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Background: Tacrolimus is a widely used calcineurin inhibitor in kidney transplantation. It is available as twice-daily
Prograf® (Tac-BID) and once-daily Advagraf® (Tac-OD). Although therapeutically equivalent, some patients require
dose adjustments to achieve similar trough concentrations [C0] after conversion. Tacrolimus exposure is affected by
ethnicity in the de novo setting but the role of ethnicity in determining dose requirements and adjustments after
conversion is unknown.
Methods: In this study, 496 renal transplant recipients (RTRs) were prospectively converted from Tac-BID to Tac-OD,
with dose adjustments targeted to achieve similar [C0] at 12 months post-conversion. Renal function, acute rejection
and Tac dose adjustments by ethnicity were analyzed.
Results: There were similar numbers of recipients from living and deceased donors. The mean transplant duration
was 7 years. Of the RTRs, 60% were Caucasian and 40% were identified as belonging to an ethnic minority. There
was no change in estimated renal function (eGFR) post-conversion to Tac-OD. At 12 months, 35/488 (7%) RTRs were
receiving a reduced dose, 101/488 (21%) required a dose increase of which 77 (16%) were receiving at least a 30%
increase in dose over baseline. The percentage of those in ethnic groups requiring a dose increase of >30% varied
from 8.0% for South Asians to 27.5% for East Asians (P = 0.03), despite East Asians having a similar baseline dose of
Tac-BID (3.59 mg/day) compared to the entire cohort (3.53 mg/day).
Conclusions: Ethnicity may play an important role in dosing requirements when converting from Tac-BID to
Tac-OD, unrelated to baseline dose. Further investigation is required to determine the reasons for ethnic variability
when patients are converted between tacrolimus preparations.Background
Tacrolimus is a widely used calcineurin-inhibitor in kidney
transplantation. It is available as both twice-daily Prograf®
(Tac-BID) and once-daily extended-release Advagraf®
(Tac-OD) (Astellas Pharma Inc, Tokyo, Japan). While
considered therapeutically equivalent [1,2], in some patients
conversion requires dose adjustments to achieve similar
trough concentrations [C0] [3]. Our previously reported de
novo experience indicated that non-Caucasians required
significantly higher doses of both Tac-BID and Tac-OD to
achieve equivalent serum concentrations [4]. However, in* Correspondence: zaltzmanj@smh.ca
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unless otherwise stated.that study the Tac-BID and Tac-OD populations were
separated by era owing to our program’s protocol switch
from the former to the latter. The effect of ethnicity on
intra-patient dosing requirements has not been previously
reported. The purpose of this prospective cohort study,
therefore, was to assess if ethnicity is an important deter-
minant of dosing requirements in a population of stable
renal transplant recipients (RTRs) undergoing conversion
from Tac-BID to Tac-OD.
Methods
The Greater Toronto Area has a population in excess of
5 million of which 43% identifies themselves as a visible
minority and 50% are foreign-born [5]. All stable RTRs
receiving Tac-BID were converted to Tac-OD in Januaryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fusion resulting from the uncontrolled switching of ta-
crolimus preparations by retail pharmacists. About 500
stable RTRs, representing the entire Tac-BID population,
were invited by appointment to initiate the switch. A
transplant pharmacist and nurse provided the rationale
for conversion and other necessary education including the
need for [C0] monitoring at 1 and 4 weeks post-conversion.
The St Michael’s Research Ethics Board approved the
study.Conversion
Patients were converted from Tac-BID to Tac-OD on a
1 mg:1 mg basis for the total daily dose unless their most
recent [C0] on Tac-BID was ≤3.0 ng/ml, in which case their
Tac-OD dose was increased by 1 mg/day. Blood samples to
measure [C0] and renal function were obtained at 1 week,
4 weeks and every 3 months post-conversion. As per the
protocol, the goal was to maintain similar [C0] levels post-
conversion. Changes in medication that could affect tacroli-
mus levels were monitored.Table 1 Baseline demographics: N = 496
Parameter Value
Age, mean (SD) 55 (12)
Male, N (%) 303 (61)
Deceased donor 249
Living donor 247
Transplant duration, years (range) 7 (0.8 to 14)
Ethnicity, N (%) 496 (100)Determination of ethnicity
Patients were classified by ethnicity based on the patient’s
self-report and/or pre-transplant assessment records [6] as
follows:
 Caucasian: any ancestry from Europe
 African Canadian: any ancestry from Africa either
directly or via the Caribbean
 East Asian: ancestry from China, Mongolia, Japan,
North or South Korea, Taiwan, Myanmar, Thailand,
Laos, Cambodia, Vietnam, Malaysia, Singapore,
Indonesia, or the Philippines
 South Asian: ancestry from India, Pakistan,
Bangladesh, Sri Lanka, Nepal, Maldives, or Bhutan
 Middle Eastern: ancestry from Egypt, Algeria, Syria,
Iraq, Iran, Lebanon, Jordan, Oman, Kuwait, Sudan,
Tunisia, Morocco, Saudi Arabia, Yemen, UAE, Libya
or the Palestinian Territories
 Other: used for various ethnicities present in low
numbers and not otherwise included above
If a patient had mixed ancestry, the patient’s self-report
was used for assignment to a single category.Caucasian, n (%) 282 (56.8)
East Asian, n (%) 91 (18.3)
South Asian, n (%) 75 (15.1)
African Canadian, n (%) 18 (3.6)
Middle Eastern, n (%) 12 (2.4)
Other, n (%) 10 (2.0)Outcomes
The primary outcome was to determine the frequency of
RTRs who at last follow-up post-conversion, required >30%
increase in Tac-OD compared to Tac-BID to achieve a
similar [C0]. Secondary outcomes included the frequency of
dose increase amongst various ethnic groups, renal functionas assessed by the modification in diet renal disease equa-
tion (eGFR) and acute rejection rates post-conversion.
Data and statistical analysis
This was a prospective cohort study with patients enter-
ing at the time of conversion from January 2012 through
May 2013, with analysis in July 2013 (3 to 18 months
follow-up).
Patient demographics, type of transplant (living ver-
sus deceased), time since transplant and ethnicity were
collected, in addition to Prograf dosage and [C0] at the
time of conversion and Advagraf dosage and [C0] post-
conversion as previously described. The data on renal
function by serum creatinine(Cr) and eGFR were col-
lected for 6 months pre-conversion to 18 months post-
conversion. However, the primary analysis of outcomes
of interest was at 12 months post-conversion. Adverse
events including episodes of biopsy-proven acute re-
jection were also recorded. The mean and standard devi-
ation (SD) of Tac dosages were collected, and the frequency
of dose increases between ethnic groups was analyzed using
a chi-square test. Renal function pre- and post-conversion
was compared using ANOVA.
Results
Between January 2012 and May 2013, 496 RTRs were
converted from Tac-BID to Tac-OD. Of the cohort, 90%
were on prednisone and 76% were also taking either
enteric-coated mycophenolic acid or mycophenolate mo-
fetil. Post-conversion, there were no changes in medication
known to interact with tacrolimus, such as diltiazem. There
were no changes in any concomitant immunosuppressive
agents. At the time of the last follow-up there were no allo-
graft losses, and no episodes of acute rejection were noted.
In the evaluation of renal function, eight patients were
excluded from final analysis based on serum creatinine






















Figure 1 Mean tacrolimus trough concentration [C0] (ng/ml), pre- and post-conversion. Arrow indicates time of conversion.
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based on conversion in patients with expected deteriorating
renal function prior to conversion. Therefore, 488 patients
were included in the renal function and tacrolimus dose ad-
justment analysis. The baseline demographics are outlined
in Table 1. As shown, there were similar numbers of recipi-
ents with living and deceased donors, the mean transplant
duration was 7 years, 56.8% of the RTRs were Caucasian
and 40% were identified as belonging to an ethnic minority
cohort.
As shown in Figure 1, at the time of conversion mean
(SD) [Tac-BID] was 5.5 (2.3) ng/ml. At one week and one
month post-conversion, [Tac-OD] decreased to 4.7 (2.0)
and 4.9 (2.1) ng/ml respectively, necessitating an increased
dose titration as per the protocol. By 9 months post-
conversion, [Tac-OD] was 5.2 (2.4) ng/ml. To maintain
a stable [tacrolimus] there were on average 0.27 dose
adjustments per patient (range: 0 to 4). Of note, by
12 months post-conversion 35/488 (7%) RTRs were re-
ceiving a reduced dose, whereas 101/488 (21%) required a
dose increase, of which 77 (16%) were receiving >30% in-
crease in dose over the baseline (Table 2). As further illus-
trated in Table 2, the percentage of patients requiring a
dose increase of 30% or greater varied from 8.0% for
South Asians to 27.5% for East Asians, the latter being
statistically significant (P = 0.03) by chi-square analysis.
We could not find any relation between initial dose andTable 2 Conversion data at 12 months by ethnicity






Total 488 3.53 (2.01) 5.49 (2.36) 3.75 (2.03)
Caucasian 282 3.23 (1.94) 5.58 (2.34) 3.42 (2.14)
East Asian 91 3.59 (2.27) 5.46 (2.35) 4.07 (2.28)
South Asian 75 3.67 (2.25) 5.00 (1.62) 3.86 (2.31)
African
Canadian
18 6.18 (3.87) 5.13 (1.43) 6.23 (4.20)
Middle
Eastern
12 3.04 (1.76) 6.39 (3.26) 2.96 (1.57)
Other 10 2.89 (2.33) 5.42 (2.37) 2.06 (2.14)
*P = 0.03 compared to all other cohorts.
BID, twice daily; OD, once daily; SD, standard deviation; Tac, tacrolimus.the dose increase for either the entire cohort or ethnic-
specific groups. As illustrated in Figure 2, there was no
change in renal function as estimated by eGFR post-
conversion.Discussion
We report on the first observational cohort trial that
demonstrates clear differences in tacrolimus dosages fol-
lowing conversion from Tac-BID to Tac-OD based on
ethnicity. Almost 500 RTRs served as their own controls
in this study, the second largest single-center conversion
study reported to date.
The potential benefit of Tac-OD versus Tac-BID is the
potential for increased patient adherence. A number of
studies have described experiences with the conversion
from Tac-BID to Tac-OD. The initial recommendation
of conversion from Tac-BID to Tac-OD was 1 mg:1 mg,
based upon pivotal studies in stable RTRs [1]. However,
with increasing experience, most groups have reported
that upon conversion, tacrolimus exposure, measured by
either C0 or area under the curve, is reduced in some
but not all RTRs [3,7-9]. Others have explored the rela-
tion with the CYP3A5 genotype, finding dose increases
upon conversion in those recipients with CYP3A5 *1/*3
or CYP3A5 *1/*1 compared to no increase in recipients




Percentage of cohort requiring >30%























Figure 2 Mean renal function by MDRD eGRF (ml/min), pre- and post-conversion. Arrow indicates time of conversion.
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RTRs. Although not reported, it is assumed by readers
that the majority of these RTRs were Caucasian [12].
The renal transplant program at St Michael’s in Toronto,
Canada, has one of the world’s most ethnically diverse pop-
ulations, comprising almost 50% new immigrants and 43%
self-identified as a visible minority. This allowed us to study
prospectively dose adjustments following conversion from
Tac-BID to Tac-OD, based on ethnicity. It has been well
established that amongst some ethnic cohorts, such as
African Americans, higher doses of tacrolimus regardless of
formulation are required, because of their faster metabol-
ism owing to a higher prevalence of CYP3A5 *1/*3 and
*1/*1 and perhaps other yet unidentified polymorphisms
[13]. This was also observed in our Toronto-based popula-
tion with African Canadians requiring an average 6.18 mg/
day compared to 3.53 mg/day for the entire cohort (P =
0.004). However, only 11% of this group of ‘fast meta-
bolizers’ as a whole, required an increase in Tac-OD
following conversion.
Our unique observation is that upon conversion, dose
increases were required with increased frequency in
distinctive ethnic groups. Of almost 500 RTRs, 15.7%
required a significant dose increase to maintain equal
C0 [Tac]. However amongst RTRs of East-Asian origin,
27.5% required a significant increase in dose upon con-
version from Tac-BID to Tac-OD. As stated earlier, there
may be a relation between being a so-called CYP3A5
expresser (*1/*1 or *1/*3) and the requirement for in-
creased tacrolimus doses on conversion from Tac-BID to
Tac-OD. However, these genotypes are not believed to
be more prevalent in the East Asian population. Of
interest, in a pediatric conversion study from Korea,
44% of the population required a dose increase while
26.5% required a decrease following conversion [7].
Niioka et al. reported 25% lower 24-hr area-under-the-
curve values in a conversion study involving Japanese
RTRs, although this was seen mainly in those with
the CYP3A5 *1/*3 genotype (15% of their cohort) [9].
Thus there may be other yet unidentified geneticpolymorphisms that have a role for certain ethnic
groups. Unlike the African Canadian cohort, the base-
line tacrolimus dosages for the East Asian population
were no different from the entire cohort (3.59 mg/day
versus 3.53 mg/day).
With regard to renal function, we did not find any differ-
ence in eGFR on conversion from Tac-BID to Tac-OD.
Although two groups have reported an improvement in
renal function following conversion [14,15], this may have
been due to reduced tacrolimus exposure following conver-
sion. A multi-center conversion study of over 1,800 RTRs
did not find any renal function change following conversion
[16]. While there may be a renal function advantage with
once daily dosing, owing to a lower single peak exposure
compared with Tac-BID, more sensitive tests of GFR are
likely needed to demonstrate this benefit if it exists [17].
Conclusions
The present study confirms that conversion from Tac-
BID to Tac-OD necessitates an increase in dosage for
some RTRs. The magnitude of this increase is affected
by ethnicity, particularly for East Asians. Since genetic
polymorphism testing is not practical for most trans-
plant programs and unlikely to be cost effective if
employed on a population-wide basis, ethnicity should be
considered in determining the initial post-conversion
Tac-OD dose. Nonetheless, pharmacogenetic and phar-
macokinetic investigations deserve consideration to better
delineate optimal conversion strategies.
Abbreviations
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deviation; Tac: tacrolimus.
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